BioSpace News Archive

Strata Precision Oncology NetworkTM now includes 10 healthcare systems providing no-cost tumor profiling and clinical trials system-wide

-- Boehringer Ingelheim and Vanderbilt University collaborate to develop novel anti-cancer drugs that inhibit the MCL1 (myeloid cell leukemia 1) protein -- There are no existing therapies targeting MCL1, which is highly prevalent in many difficult-to-treat cancers -- This is the third collaboration between Boehringer Ingelheim and Vanderbilt University

Arrevus Inc., a biotechnology company developing chaperone protein inhibitors to combat antimicrobial resistance, announced the addition of three new board members: Barry Garfinkle, Joe McMahon, and Joe St. Geme.

Unprecedented Clinical Data Could Capture $3B Uncontested Market

(A Non-Randomized Study Evaluating the Use of the Reflow Medical Wingman Catheter to Cross Chronic Total Occlusions in Infrainguinal Peripheral ArTeries)

Cardiome Pharma Corp. reported financial results for its fourth quarter and year ended December 31, 2017 and commented on recent accomplishments and plans.

ImmunoCellular Therapeutics, Ltd. announced financial results for the fourth quarter and full year ended December 31, 2017.

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market Renevia® in Europe.

Patented UV technology proven to provide cleaner, safer operating environments

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Troy Hamilton, Chief Executive Officer of Synergy, will present a corporate update at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern Time at the Westin New York Grand Central in New York City.